The Medicines Company announces that the ORION-10 study of inclisiran showed durable and potent lowering of LDL-C

This article was originally published here

In ORION-10, twice-yearly dosing with inclisiran sodium 300 mg met all primary and secondary efficacy endpoints, was well-tolerated and again demonstrated an excellent safety profile. Full study results

The post The Medicines Company announces that the ORION-10 study of inclisiran showed durable and potent lowering of LDL-C appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply